AB0810 SEROLOGICAL AND/OR IMMUNOLOGICAL BIOMARKERS INFLUENCE THE CLINICAL PHENOTYPE OF EXTRAGLANDULAR MANIFESTATIONS IN PRIMARY SJÖGREN’S SYNDROME
Authors: C. Sieiro Santos, J. Torguet, H. S. Park, J. L. Tandaipan, B. P. Magallares, P. Moya, C. Díaz-Torné, S. P. Fernandez-Sanchez, A. Laiz, L. Sainz Comas, H. Codes, S. Ros, I. Castellví, E. Diez Álvarez, H. Corominas
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Primary Sjögren's Syndrome (pSS) is a systemic autoimmune disease characterized by salivary gland involvement. Some patients may develop systemic extra glandular manifestations that can determine the prognosis of the disease. The influence of serological and immunological biomarkers on the clinical expression of the disease is still not fully known, nor is their role as prognostic factors of the disease. <h3>Objectives:</h3> The aim of the study was to assess the prevalence of extraglandular involvement in pSS, as well as to determine the relationship between immunological and serological biomarkers, disease activity, and extraglandular manifestations in patients with pSS. <h3>Methods:</h3> A cohort of patients with pSS who met the ACR/EULAR classification criteria for pSS in 2016 followed up in our Systemic Autoimmune Diseases Unit between 2000 and 2022 was carried out. The sociodemographic, clinical, serological and immunological data and the Disease activity measures calculated with the ESSDAI index (EULAR Sjögren's Syndrome disease activity index) were collected. For the comparison of qualitative and/or quantitative variables, Fisher's exact test or the T-test was performed when necessary. <h3>Results:</h3> 175 patients with pSS were included (85% were women), with a mean age at diagnosis of 58.8±12.2 years and a disease evolution time of 7.6±5.4 years. 62 patients (35%) had extraglandular manifestations. Anti-Ro60 positivity was found in 68%, Anti-Ro52 in 35.3% and anti-Ro60 and anti-La in 47.4% of patients. Associations between serological markers and systemic manifestations in patients with pSS is summarized in Graph 1 and Table 1. A higher risk of renal involvement was found in anti-Ro60, meanwhile a lung involvement, hypocomplementemia and higher levels of rheumatoid factor and hypergammaglobulinemia were associated with anti-Ro52 positivity. Constitutional symptoms, hematological involvement, lymphadenopathy, higher erythrocyte sedimentation rate and ESSDAI score were associated with both anti-Ro and anti-La positivity. Cutaneous involvement was specifically associated with anti-Ro52, C3 levels, IgG and IgM levels. Articular involvement was associated with higher rheumatoid factor levels. Renal involvement was associated with C3 levels, rheumatoid factor, ESR levels, IgG levels and anti-Ro60. Lung involvement was associated with ESR levels and C-reactive protein, IgG, C3 levels and anti-Ro52 positivity. CNS involvement was associated with C3 levels, C-reactive protein and beta2microglobulin and hematological involvement with C3, rheumatoid factor, beta2microglobulin and IgG levels. <h3>Conclusion:</h3> Our results have demonstrated the role of immunological and serological biomarkers in the clinical expression of pSS and as prognostic factors for disease progression, as well as their applicability in clinical practice. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>